Abstract 6666: Deriving high-fidelity, low-plex clinical signatures from ultra-high-plex spatial data for immunotherapy response prediction

Abstract Background: Ultra-high-plex multiplex immunofluorescence (mIF) imaging enables detailed characterization of the tumor microenvironment (TME), yet translating these rich datasets into clinically deployable, low-plex biomarkers remains a major barrier for precision immuno-oncology. Existing predictive models rely heavily on high-dimensional features or broad phenotypic panels, limiting scalability, interpretability, and routine pathology integration. A systematic framework is needed to compress spatially resolved molecular information into minimal, clinical-plex, yet highly informative signatures capable of predicting immunotherapy response. Methods: Our SpaceIQ™ platform is a multi-omic analysis tool that integrates spatial proteomics data with optimized feature selection algorithms to distill molecular signatures. We employ unbiased cell typing and microdomain discovery to identify a differentially expressed network of spatial interactions between these unbiased cell types, utilizing pointwise mutual information (PMI) analysis. Each interaction (either pairwise or higher-order cliques) within this network represents a potential spatial prognostic model capable of predicting patient response. A key component of our approach is the identification of a subset threshold cell population that is enriched for a given unbiased cell type using a low-plex panel. The final prognostic model for a differential clique combines a spatial proximity score with these low-plex marker intensities. Results: Analysis of ultra-high-plex (=51 markers) spatial data from trial specimens of checkpoint-treated cutaneous T-cell lymphoma patients demonstrated that tumor-immune and immune-immune interactions emerge as microdomains with minimal signatures of 6-8 markers and high prediction accuracies (AUC = 0.87, 95% CI (0.865-0.881)). Conclusions: The SpaceIQ platform enables the extraction of compact, clinically practical biomarker panels from ultra-high-plex mIF datasets without sacrificing predictive power. By linking spatial microdomain biology to sparse signature derivation, this framework supports scalable deployment of precision immunotherapy biomarkers and enhances patient-selection strategies in clinical practice. Citation Format: Raymond Yan, Brian Falkenstein, A. Burak Tosun, Filippo Pullara, S. Chakra Chennubhotla. Deriving high-fidelity, low-plex clinical signatures from ultra-high-plex spatial data for immunotherapy response prediction [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6666.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-6666
Primary Topic
Single-cell and spatial transcriptomics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 6666: Deriving high-fidelity, low-plex clinical signatures from ultra-high-plex spatial data for immunotherapy response prediction

Filippo Pullara, S. Chakra Chennubhotla, Brian Falkenstein, Raymond Yan et al.
Cancer Research
Single-cell and spatial transcriptomics
article

Abstract 6666: Deriving high-fidelity, low-plex clinical signatures from ultra-high-plex spatial data for immunotherapy response prediction

Filippo Pullara, S. Chakra Chennubhotla, Brian Falkenstein, Raymond Yan, A. Burak Tosun
article en

Abstract

Abstract Background: Ultra-high-plex multiplex immunofluorescence (mIF) imaging enables detailed characterization of the tumor microenvironment (TME), yet translating these rich datasets into clinically deployable, low-plex biomarkers remains a major barrier for precision immuno-oncology. Existing predictive models rely heavily on high-dimensional features or broad phenotypic panels, limiting scalability, interpretability, and routine pathology integration. A systematic framework is needed to compress spatially resolved molecular information into minimal, clinical-plex, yet highly informative signatures capable of predicting immunotherapy response. Methods: Our SpaceIQ™ platform is a multi-omic analysis tool that integrates spatial proteomics data with optimized feature selection algorithms to distill molecular signatures. We employ unbiased cell typing and microdomain discovery to identify a differentially expressed network of spatial interactions between these unbiased cell types, utilizing pointwise mutual information (PMI) analysis. Each interaction (either pairwise or higher-order cliques) within this network represents a potential spatial prognostic model capable of predicting patient response. A key component of our approach is the identification of a subset threshold cell population that is enriched for a given unbiased cell type using a low-plex panel. The final prognostic model for a differential clique combines a spatial proximity score with these low-plex marker intensities. Results: Analysis of ultra-high-plex (=51 markers) spatial data from trial specimens of checkpoint-treated cutaneous T-cell lymphoma patients demonstrated that tumor-immune and immune-immune interactions emerge as microdomains with minimal signatures of 6-8 markers and high prediction accuracies (AUC = 0.87, 95% CI (0.865-0.881)). Conclusions: The SpaceIQ platform enables the extraction of compact, clinically practical biomarker panels from ultra-high-plex mIF datasets without sacrificing predictive power. By linking spatial microdomain biology to sparse signature derivation, this framework supports scalable deployment of precision immunotherapy biomarkers and enhances patient-selection strategies in clinical practice. Citation Format: Raymond Yan, Brian Falkenstein, A. Burak Tosun, Filippo Pullara, S. Chakra Chennubhotla. Deriving high-fidelity, low-plex clinical signatures from ultra-high-plex spatial data for immunotherapy response prediction [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6666.

Cancer ResearchVol. 86(7_Supplement)
University of Pittsburgh (US)
Openalex Percentile: Top 28%
Single-cell and spatial transcriptomics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.